Medical Retina Fellowship

在流行病学和临床应用司下属的国家眼科研究所进行了一些视网膜医用方案。这包括多种常见和罕见视网膜疾病的介入性研究(I期和/或II期)和自然史研究。这些疾病包括老年性黄斑变性(AMD)、糖尿病视网膜病变、视网膜静脉阻塞、黄斑毛细血管扩张、羟氯喹视网膜毒性、中心性浆液性脉络膜视网膜病变、遗传性视网膜疾病和Von Hippel Lindau(VHL)病。此外，一项筛选研究为这些试验和自然历史研究的潜在招募提供了参与者。 这些干预性研究包括与使用小胶质细胞抑制剂治疗AMD的地理萎缩相关的研究；治疗VHL视网膜疾病的新疗法(与国家癌症研究所合作)；X连锁视网膜劈裂的基因治疗方法；以及针对2型黄斑毛细血管扩张的神经保护治疗。 自然病史研究包括与AMD相关的多项研究(老年性眼病随访研究(AREDS)和AREDS2；AMD患者的暗适应研究；AMD Ryan Initiative研究；地理萎缩自然病史研究)，以及与羟氯喹视网膜毒性和黄斑毛细血管扩张相关的研究。生物库协议包括为多种视网膜疾病采集血液(DNA)。其他正在进行的合作研究包括HIV相关神经退行性变患者(NINDS)的视网膜发现，以及AMD的基因-表型研究(NHGRI)。

A number of medical retinal protocols have been conducted at the National Eye Institute under the Division of Epidemiology and Clinical Applications. This includes both interventional studies (phase I and/or or II) and natural history studies for multiple common and rare retinal diseases. These include age-related macular degeneration (AMD), diabetic retinopathy, retinal vein occlusion, macular telangiectasia, hydroxychloroquine retinal toxicity, central serous chorioretinopathy, inherited retinal diseases, and Von Hippel Lindau (VHL) disease. In addition, a screening study provides participants for potential recruitment to these trials and natural history studies. The interventional studies include those related to treatment with a microglial inhibitor for geographic atrophy in AMD; novel treatments for retinal disease in VHL (in collaboration with the National Cancer Institute); a gene therapy approach for X-linked retinoschisis; and a neuroprotective treatment for macular telangiectasia type 2. The natural history studies include multiple related to AMD (follow up of Age-Related Eye Disease Study (AREDS) and AREDS2; studies of dark adaptation in patients with AMD; the AMD Ryan Initiative Study; the geographic atrophy natural history study), as well as those related to hydroxychloroquine retinal toxicity and macular telangiectasia. The Biobank protocol includes collection of blood (DNA) for multiple retinal diseases. Other collaborative studies underway include retinal findings in individuals with HIV-related neurodegeneration (with NINDS), and genotype-phenotype studies of AMD (with NHGRI).